Insider Selling: Zai Lab (NASDAQ:ZLAB) Insider Sells $188,017.41 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 10,787 shares of Zai Lab stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total transaction of $188,017.41. Following the completion of the sale, the insider owned 52,391 shares of the company’s stock, valued at $913,175.13. This represents a 17.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Zai Lab Trading Down 1.8%

NASDAQ:ZLAB opened at $17.33 on Monday. Zai Lab Limited Unsponsored ADR has a 12 month low of $16.82 and a 12 month high of $44.34. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -8.89 and a beta of 0.83. The firm has a fifty day simple moving average of $20.37 and a two-hundred day simple moving average of $29.10.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Zai Lab had a negative return on equity of 25.83% and a negative net margin of 46.83%.The company had revenue of $116.10 million for the quarter, compared to the consensus estimate of $150.24 million. Equities analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $56.35.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ZLAB. SG Americas Securities LLC bought a new stake in Zai Lab during the third quarter worth $331,000. Royal Bank of Canada boosted its holdings in Zai Lab by 214.3% during the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company’s stock worth $498,000 after acquiring an additional 9,390 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Zai Lab during the 1st quarter worth $1,073,000. Cubist Systematic Strategies LLC boosted its holdings in Zai Lab by 29.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company’s stock worth $3,384,000 after acquiring an additional 21,026 shares during the last quarter. Finally, Raymond James Financial Inc. grew its stake in shares of Zai Lab by 219.6% in the 1st quarter. Raymond James Financial Inc. now owns 125,967 shares of the company’s stock worth $4,552,000 after acquiring an additional 86,547 shares in the last quarter. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.